Cancerous and benign growths can be removed through the use of a non-invasive, experimental device that uses focused ultrasound to break up the tumors. The system, ExAblate 2000, developed by the Israeli InSightec company, is tracked in real-time using an MRI scanner. The treatment is being clinically tested for use in fighting breast cancer, brain tumors and uterine fibroids, and it may preclude the need for many hysterectomies regularly performed today.
While experimental trials are underway in medical centers around the world, in Israel, the treatment is already being implemented regularly at Haddasah and Sheba hospitals. And it will shortly be included in the coverage offered by one of Israel’s central health funds, Maccabee, for uterine myoma treatment. At this point, the InSightec treatment for benign uterine tumors has been approved for the general public in Israel, Japan and Europe.
InSightec, founded in 1999, is a joint venture of Elbit Medical Imaging and General Electric Medical Sytems.
While experimental trials are underway in medical centers around the world, in Israel, the treatment is already being implemented regularly at Haddasah and Sheba hospitals. And it will shortly be included in the coverage offered by one of Israel’s central health funds, Maccabee, for uterine myoma treatment. At this point, the InSightec treatment for benign uterine tumors has been approved for the general public in Israel, Japan and Europe.
InSightec, founded in 1999, is a joint venture of Elbit Medical Imaging and General Electric Medical Sytems.